Pioneering research shows drug can purge dormant HIV

July 25, 2012

Researchers from the University of North Carolina at Chapel Hill have published pioneering research showing that a drug used to treat certain types of lymphoma was able to dislodge hidden virus in patients receiving treatment for HIV.

The existence of persistent reservoirs of dormant in the immune system that are not attacked by anti- is believed to be a major reason why infection reemerges once patients stop taking their medication. The disruption and clearance of these reservoirs is critical to finding a cure for AIDS.

The study was published in the July 25 issue of the leading scientific journal, Nature.

Researchers at UNC, working in collaboration with scientists from the Harvard School of Public Health, , Merck, and the University of California at San Diego, undertook a series of experiments designed to evaluate the potential of the drug vorinostat, a deacetylase inhibitor that is used to treat some types of lymphoma, to activate and disrupt the dormant .

Initially, laboratory experiments measuring active HIV levels in CD4+ T cells, which are specialized that the virus uses to replicate, showed that vorinostat unmasked the hidden virus in these cells. Subsequently, vorinostat was administered to eight HIV-infected men who were medically stable on antiretroviral therapy and the levels of active were measured and compared to the levels prior to administration.

Those patients receiving vorinostat showed an average 4.5-fold increase in the levels of HIV RNA in CD4+ T cells, evidence that the virus was being unmasked. This is the first published study to show the potential for deacetylase inhibitors to attack latency within dormant virus pools in a translational clinical study.

"This work provides compelling evidence for a new strategy to directly attack and eradicate latent HIV infection," said David Margolis, MD, professor of medicine, microbiology and immunology, and epidemiology at the University of North Carolina at Chapel Hill. Targeting latency is the first step on a path that may lead to a cure.

"Long-term, widespread use of antiretrovirals has personal and public health consequences, including side effects, financial costs, and community resistance," said Margolis, who led the study. "We must seek other ways to end the epidemic, and this research provides new hope for a strategy to eradicate HIV completely from the body."

Explore further: Drug helps purge hidden HIV virus, study shows

More information: Early results of this study were first presented and reported in March 2012 at the Conference on Retroviruses and Opportunistic Infections in Seattle, Washington.

Related Stories

Drug helps purge hidden HIV virus, study shows

March 8, 2012
A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.

HIV hides soon after infection, research shows

May 30, 2012
(Medical Xpress) -- A team of researchers led by the University of North Carolina School of Medicine has demonstrated that latency develops soon after infection and slows when antiretroviral therapy is given.

AIDS cure may have two main pathways: experts (Update)

July 24, 2012
Investigators are looking into two main paths toward a cure for AIDS, based on the stunning stories of a small group of people around the world who have been able to overcome the disease.

Vaccination strategy may hold key to ridding HIV infection from immune system

March 8, 2012
Using human immune system cells in the lab, AIDS experts at Johns Hopkins have figured out a way to kill off latent forms of HIV that hide in infected T cells long after antiretroviral therapy has successfully stalled viral ...

Drug designer: New tool reveals mutations that cause HIV-drug resistance

July 8, 2011
Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new ...

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.